Surreal illustration of a healthy liver intertwined with antiviral medication.

Decoding Liver Health: A Simple Guide to Glecaprevir and Pibrentasvir

Lena Kashyap monogram
Lena Kashyap in Health & Wellness October 2026 • 3 min read.

"Everything you need to know about these antivirals and how they interact with your liver function."


Chronic liver diseases, including those caused by the hepatitis C virus (HCV), affect millions worldwide. Understanding how medications impact the liver is crucial, especially for those with impaired liver function. Antiviral drugs like glecaprevir and pibrentasvir have revolutionized HCV treatment, but how do they behave in individuals with different levels of liver health?

This guide simplifies a complex study published in the European Journal of Clinical Pharmacology, focusing on how glecaprevir and pibrentasvir, two direct-acting antivirals (DAAs), are processed by the body in people with varying degrees of hepatic impairment (liver damage). The goal is to provide clear, actionable information without overwhelming you with technical jargon.

We'll explore the key findings of the study, explaining the implications for individuals with mild, moderate, or severe liver impairment, and what it means for the effectiveness and safety of these medications.

AI Search Multiple angles on this topic

Available Data and Digital Measurement

The supplied sources do not provide statistics about liver health, glecaprevir, or pibrentasvir. Microsoft Forms is described as a tool for creating surveys, quizzes, and polls, with results visible as responses arrive. Its built-in analytics and Excel export could support response analysis, but these sources do not establish any medical findings.

Evidence Is Not Provided

No source material was supplied for this subsection. Accordingly, no specific standard treatment approach, accepted method, or limitation can be established here. Any discussion of liver-health care would require medically relevant sources.

Telecommunications Milestones

The supplied historical sources concern Taiwan's prepaid telecommunications market rather than liver medicine. One source reports that Taiwan's 3G networks closed in 2024, making VoLTE calling more prominent and increasing attention to signal stability, VoWiFi, and VoLTE support. Other sources discuss 2026 comparisons of 4G and 5G plans, prepaid eSIM availability, and Chunghwa Telecom data packages valid for 60, 120, or 180 days.

What You Need to Know About Glecaprevir and Pibrentasvir

Surreal illustration of a healthy liver intertwined with antiviral medication.

Glecaprevir and pibrentasvir are direct-acting antivirals (DAAs) used in combination to treat chronic hepatitis C infection. These medications work by targeting specific proteins that the hepatitis C virus needs to replicate, effectively stopping the virus from spreading and causing further liver damage. The combination is often prescribed as a once-daily, fixed-dose regimen.

The original study investigated how the body processes these drugs (pharmacokinetics) in people without HCV but with different levels of liver impairment. Participants were divided into groups based on their Child-Pugh scores, which measure the severity of liver disease:

  • Normal hepatic function
  • Mild impairment (CP-A)
  • Moderate impairment (CP-B)
  • Severe impairment (CP-C)
AI Search Multiple angles on this topic

No Relevant Research Supplied

No source material was supplied for this subsection. The available information therefore does not support a specific claim about recent research or reviews of glecaprevir and pibrentasvir. Medical conclusions should not be inferred without relevant clinical or regulatory sources.

No Relevant Evidence Supplied

No source material was supplied for this subsection. It is therefore not possible to identify evidence-based counterarguments, treatment failures, or limitations concerning glecaprevir and pibrentasvir. Any such discussion would require sources directly addressing the medicines or liver-health outcomes.

Comparison of Acura ADX Offers

The supplied comparison sources concern leasing offers for the 2026 Acura ADX, not antiviral medicines. One dealer listing reports $419 per month for the 2026 ADX AWD and $449 per month for the AWD A-SPEC, with $2,000 due at signing for a 36-month, 10,000-mile-per-year lease. CarsDirect reports offers from $369 per month and financing as low as 3.99% APR, while noting that deals are updated daily and may vary by area.

Each group received single doses of pibrentasvir alone or in combination with glecaprevir. Researchers then measured the levels of the drugs in the blood to see how liver function affected drug absorption, distribution, metabolism, and excretion.

The Bottom Line: What This Means for You

This study highlights the importance of understanding how liver function affects drug metabolism, particularly for medications like glecaprevir and pibrentasvir. While the glecaprevir/pibrentasvir combination is generally safe and effective for those with mild liver impairment, individuals with moderate to severe impairment may experience significantly altered drug exposures. Always consult your healthcare provider. This information is intended to educate and should not substitute for professional medical advice.

AI Search Multiple angles on this topic

Evidence-Based Synthesis

No source material was supplied for this subsection. A responsible synthesis of glecaprevir and pibrentasvir would need sources that directly address their use, effectiveness, safety, and clinical context. The supplied unrelated sources cannot support expert commentary on liver health.

Future Evidence Needed

No source material was supplied for this subsection. Future developments involving glecaprevir and pibrentasvir cannot be described from the available material. Relevant clinical research, regulatory updates, or implementation evidence would be needed.

Context Requires Medical Sources

No source material was supplied for this subsection. The available sources do not address healthcare access, affordability, health systems, or other systemic challenges related to liver disease treatment. Those issues should be discussed only with directly relevant evidence.

Language Access and Communication

The supplied sources show that Google Translate offers free translation of words, phrases, and web pages between English and more than 100 other languages. The French-language Google Traduction pages likewise describe instant translation services. These sources support the relevance of multilingual communication, but they do not establish how translation affects people receiving liver-health care.

Drug exposure across liver-function groups

  • 6The pharmacokinetic comparison used single doses of pibrentasvir alone or with glecaprevir in HCV-negative participants grouped by liver function; each functional group and dose included 6 participants.[1]
  • 160% and 21%Another comparison found glecaprevir AUC 160% higher and pibrentasvir AUC 21% higher in HCV-infected participants with Child-Pugh A cirrhosis than in those without cirrhosis.[2]
  • 33%A separate report described a 33% increase in glecaprevir plasma exposure in compensated cirrhosis relative to normal liver function.[3]

What exposure comparisons can tell us

Across the cited comparisons, cirrhosis is associated with greater glecaprevir exposure, while the reported pibrentasvir changes are smaller or described as similar. These observations come from HCV-infected populations with cirrhosis, not the small, single-dose comparison in HCV-negative people with different impairment levels, so they do not establish the same pattern for every liver-function group.[1] [2] [4]

How related sources frame exposure and metabolism

A liver-tissue analysis measured drug-metabolizing enzyme protein and mRNA in hepatitis C samples across Child-Pugh classes. It reported increased UGT1A1 in class A and reductions in several enzymes in class B, with reduced CYP1A2 in class C; these tissue findings provide biological context, not direct measurements of glecaprevir or pibrentasvir exposure.[5]

Later clinical and regulatory material raises context beyond pharmacokinetics: a review notes that glecaprevir can raise levels of certain statins, while FDA material says safety at exposures above fivefold was not adequately informed and safety margins could not be established from Phase 3 experience. These statements concern interaction and evidence boundaries, not proof of harm at a particular exposure.[6] [7]

A product description identifies glecaprevir as an NS3/4A protease inhibitor and pibrentasvir as an NS5A inhibitor; a later clinical-practice update describes an 8-week regimen for treatment-naïve people with compensated cirrhosis. These sources add mechanism and treatment-context detail, but do not change what the pharmacokinetic comparisons measured.[8] [9]

What the exposure evidence leaves unresolved

  • How should increased exposure in cirrhosis be interpreted alongside the limited safety information at higher exposures and the reported statin interaction? The cited sources do not resolve those questions as a single combined assessment.[4] [6] [7]

Sources

  1. Pharmacokinetics and safety of glecaprevir and pibrentasvir in HCV-negative subjects with hepatic impairment. (doi.org, 2018)
  2. Population Pharmacokinetics of Glecaprevir/Pibrentasvir in HCV-infected Japanese Subjects in Phase 3 CERTAIN-1 and CERTAIN-2 Trials. (pubmed.ncbi.nlm.nih.gov)
  3. Risk Factors of Glecaprevir/Pibrentasvir-Induced Liver Injury and Efficacy of Ursodeoxycholic Acid (2023)
  4. Safety and Pharmacokinetics of Glecaprevir/Pibrentasvir in Adults With Chronic Genotype 1–6 Hepatitis C Virus Infections and Compensated Liver Disease (pmc.ncbi.nlm.nih.gov)
  5. Protein Abundance of Drug Metabolizing Enzymes in Human Hepatitis C Livers (International Journal of Molecular Sciences, 2023)
  6. Glecaprevir/Pibrentasvir Versus Sofosbuvir/Velpatasvir for Hepatitis C Virus Genotype 6: A Systematic Review and Meta‐Analysis (2025)
  7. www.accessdata.fda.gov (www.accessdata.fda.gov)
  8. Maviret, INN-glecaprevir,pibrentasvir (www.ema.europa.eu)
  9. AASLD/IDSA 2023 Clinical Practice Guidance Update for Testing, Managing, and Treating Hepatitis C Virus Infection (www.idsociety.org)

About this Article -

Written with AI assistance from published research, and reviewed by the Mystum team. See our About page for more information.

This article is based on research published under:

DOI-LINK: 10.1007/s00228-018-2576-4, Alternate LINK

Title: Pharmacokinetics And Safety Of Glecaprevir And Pibrentasvir In Hcv-Negative Subjects With Hepatic Impairment

Subject: Pharmacology (medical)

Journal: European Journal of Clinical Pharmacology

Publisher: Springer Science and Business Media LLC

Authors: Matthew P. Kosloski, Haoyu Wang, David Pugatch, Federico J. Mensa, Edward Gane, Eric Lawitz, Thomas C. Marbury, Richard A. Preston, Jens Kort, Wei Liu

Published: 2018-10-19

Everything You Need To Know

1

What exactly are glecaprevir and pibrentasvir, and how do they work against hepatitis C?

Glecaprevir and pibrentasvir are direct-acting antiviral medications (DAAs) specifically designed to combat the hepatitis C virus (HCV). They function by targeting essential proteins that HCV needs to replicate. By inhibiting these proteins, the medications prevent the virus from multiplying and causing further liver damage. This combination therapy is commonly administered as a once-daily, fixed-dose regimen, simplifying the treatment process for patients.

2

What is the Child-Pugh score, and why is it relevant to understanding liver health in the context of this?

The Child-Pugh score is a clinical assessment tool used to evaluate the severity of liver disease. It categorizes liver impairment into different levels: normal hepatic function, mild impairment (CP-A), moderate impairment (CP-B), and severe impairment (CP-C). This scoring system is crucial for understanding how well the liver is functioning and how it might affect the way the body processes drugs like glecaprevir and pibrentasvir.

3

How does the level of liver impairment affect the effectiveness and safety of glecaprevir and pibrentasvir?

The study showed that the way the body handles glecaprevir and pibrentasvir can be affected by the health of your liver. For those with mild liver impairment, the combination is usually safe and works well. However, if someone has moderate to severe liver impairment, they might experience significant changes in how much of the drug their body is exposed to. This means the drug might not work as well or could cause more side effects, highlighting the importance of medical consultation.

4

Can you explain 'pharmacokinetics' in simple terms and why it's important when considering glecaprevir and pibrentasvir?

Pharmacokinetics refers to how the body processes a drug, including absorption, distribution, metabolism, and excretion. When it comes to glecaprevir and pibrentasvir, pharmacokinetics is crucial because liver impairment can significantly alter these processes. This can lead to higher or lower drug concentrations in the body, affecting both the effectiveness and safety of the treatment. Understanding these pharmacokinetic changes helps in tailoring dosages to match individual liver function.

5

Besides the severity of liver impairment, what other factors should be considered when using glecaprevir and pibrentasvir for HCV treatment?

While glecaprevir and pibrentasvir have revolutionized HCV treatment, their interaction with other medications is an important consideration. Certain drugs may interfere with their metabolism, potentially leading to increased side effects or reduced effectiveness. Additionally, the presence of co-existing liver conditions beyond HCV can further complicate treatment strategies. Therefore, a thorough review of a patient's complete medication list and overall liver health is essential before initiating therapy with glecaprevir and pibrentasvir to optimize outcomes and minimize risks.

Newsletter Subscribe

Subscribe to get the latest articles and insights directly in your inbox.